337 related articles for article (PubMed ID: 28384657)
1. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Pramanik R; Agarwala S; Gupta YK; Thulkar S; Vishnubhatla S; Batra A; Dhawan D; Bakhshi S
JAMA Oncol; 2017 Sep; 3(9):1222-1227. PubMed ID: 28384657
[TBL] [Abstract][Full Text] [Related]
2. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A; Chocholous M; Sabel M; Lassaletta A; Sterba J; Leblond P; Nysom K; Torsvik I; Chi SN; Perwein T; Jones N; Holm S; Nyman P; Mörse H; Öberg A; Weiler-Wichtl L; Leiss U; Haberler C; Schmook MT; Mayr L; Dieckmann K; Kool M; Gojo J; Azizi AA; André N; Kieran M; Slavc I
JAMA Oncol; 2023 Dec; 9(12):1688-1695. PubMed ID: 37883081
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
Munzone E; Regan MM; Cinieri S; Montagna E; Orlando L; Shi R; Campadelli E; Gianni L; Palleschi M; Petrelli F; Bengala C; Generali D; Collovà E; Puglisi F; Cretella E; Zamagni C; Chini C; Ruepp B; Loi S; Colleoni M;
JAMA Oncol; 2023 Sep; 9(9):1267-1272. PubMed ID: 37440239
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
8. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma.
Perret A; Dômont J; Chamseddine AN; Dumont SN; Verret B; Briand S; Court C; Lazure T; Adam J; Ngo C; Even C; Levy A; Bayle A; Lucibello F; Haddag-Miliani L; Faron M; Honoré C; Le Cesne A; Mir O
Cancer Med; 2021 Jan; 10(1):230-236. PubMed ID: 33236839
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
[TBL] [Abstract][Full Text] [Related]
14. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
15. SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor.
Heng-Maillard MA; Verschuur A; Aschero A; Dabadie A; Jouve E; Chastagner P; Leblond P; Aerts I; De Luca B; André N
Pediatr Blood Cancer; 2019 Jul; 66(7):e27693. PubMed ID: 30920117
[TBL] [Abstract][Full Text] [Related]
16. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies.
El Kababri M; Benmiloud S; Cherkaoui S; El Houdzi J; Maani K; Ansari N; Khoubila N; Kili A; El Khorassani M; Madani A; Tazi MA; Ahid S; Hessissen L; Quessar A; Harif M; Khattab M; André N
Pediatr Blood Cancer; 2020 Sep; 67(9):e28508. PubMed ID: 32658380
[TBL] [Abstract][Full Text] [Related]
17. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
18. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
[TBL] [Abstract][Full Text] [Related]
19. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center.
Lu Q; Lee K; Xu F; Xia W; Zheng Q; Hong R; Jiang K; Zhai Q; Li Y; Shi Y; Yuan Z; Wang S
Cancer Commun (Lond); 2020 May; 40(5):222-233. PubMed ID: 32390331
[TBL] [Abstract][Full Text] [Related]
20. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]